FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

Dow Jones

11/22

By Kelly Cloonan

The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC).

The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication.

A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

November 21, 2025 12:52 ET (17:52 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585622140"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585622140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585622140?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-22 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585622140","market":"nz","top_or_hot":-1,"title":"FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). \n</p>\n<p>\n  The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication. \n</p>\n<p>\n  A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2025 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-22 01:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). \n</p>\n<p>\n  The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication. \n</p>\n<p>\n  A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2025 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2585622140","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585622140","pubTimestamp":1763747520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer .The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication.A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0861579265.USD":"联博低波幅策略股票基金A","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4516":"特朗普概念","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","ALPMY":"Astellas Pharma, Inc.","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","MRK":"默沙东","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"FDA批准默沙东的Keytruda联合安斯泰来的Padcev治疗膀胱癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1.5,"ALPMY":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). \n\n\n  The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication. \n\n\n  A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 12:52 ET (17:52 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}